A5047539709- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Cancer-related gene regulation
- Melanoma and MAPK Pathways
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Treatment and Pharmacology
- Phagocytosis and Immune Regulation
- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy
- Immunotherapy and Immune Responses
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- PI3K/AKT/mTOR signaling in cancer
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- CAR-T cell therapy research
- Axon Guidance and Neuronal Signaling
- Epigenetics and DNA Methylation
European Institute of Oncology
2023-2025
University of Campania "Luigi Vanvitelli"
2014-2024
Casa Sollievo della Sofferenza
2021-2023
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2023
Vall d'Hebron Institute of Oncology
2020-2023
Universitat de Vic - Universitat Central de Catalunya
2021-2023
Hebron University
2023
Vall d'Hebron Hospital Universitari
2020-2021
Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli
2019
Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment cetuximab plus avelumab overall survival (OS) may be worthy investigation this setting.To assess the efficacy and safety rechallenge avelumab.This single-arm, multicenter phase 2 trial enrolled from August 2018 February...
Previous studies showed that the combination of an anti-Epidermal growth factor (EGFR) and a MEK-inhibitor is able to prevent onset resistance anti-EGFR monoclonal antibodies in KRAS-wild type colorectal cancer (CRC), while same reverts primary KRAS mutated CRC cell lines. However, rapid limit therapies CRC.We generated four different lines resistant cetuximab (an antibody) refametinib (a selective MEK-inhibitor) after continuous exposure increasing concentration drugs. We characterized...
Abstract Purpose: OncoBEAM™ is a circulating tumor DNA (ctDNA) test that uses the BEAMing digital PCR technology. We clarified association between baseline burden and discordance in RAS status by metastatic sites patients with single site. Experimental Design: Data from previous Spanish Japanese studies investigating concordance of tissue biopsy 221 colorectal cancer (mCRC) were used. collected data liver, peritoneal, or lung metastases evaluated rates according to site rate burden. Results:...
Gut microbiota is involved in immune modulation and checkpoint inhibitors (ICIs) efficacy. Single-arm phase II CAVE-mCRC CAVE-LUNG clinical trials investigated cetuximab + avelumab combination RAS wild-type (WT) metastatic colorectal cancer (mCRC) chemo-refractory nonsmall cell lung (NSCLC) patients, respectively. A comprehensive gut genetic analysis was done basal fecal samples of 14 patients from trial with circulating tumor DNA (ctDNA) RAS/BRAF WT microsatellite stable (MSS) disease....
Metastatic colorectal cancer (mCRC) patients tend to have modest benefits from molecularly driven therapeutics. Patient-derived tumor organoids (PDTOs) represent an unmatched model elucidate resistance therapy, due their high capacity resemble characteristics.We used viable tissue two cohorts of with mCRC, naïve or refractory treatment, respectively, for generating PDTOs. The derived models were subjected a 6-day drug screening assay (DSA) comprehensive pipeline chemotherapy and targeted...
Importance The available evidence regarding anti–epidermal growth factor receptor (EGFR) inhibitor rechallenge in patients with refractory circulating tumor DNA (ctDNA) RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) is derived from small retrospective and prospective studies. Objective To evaluate the efficacy of anti-EGFR ctDNA wt mCRC. Design, Setting, Participants This nonrandomized controlled trial used a pooled analysis individual patient data mCRC enrolled 4 Italian trials...
The EPHA2 tyrosine kinase receptor is implicated in tumor progression and targeted therapies resistance. We evaluated as a potential resistance marker to the antiepidermal growth factor (EGFR) monoclonal antibody cetuximab colorectal cancer. studied activation of panel human cancer cell lines sensitive or resistant anti-EGFR drugs. vitro vivo effects ALW-II-41-27 (an inhibitor) and/or treatment were tested. Formalin-fixed paraffin-embedded specimens from 82 RAS wild-type (WT) metastatic...
Abstract Osimertinib is a third-generation tyrosine kinase inhibitor clinically approved for first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients. Although an impressive drug response initially observed, in most tumors, resistance occurs after different time and alternative therapeutic strategy to induce regression disease currently lacking. The hyperactivation MEK/MAPKs, one the common event identified osimertinib-resistant (OR) NSCLC cells. However, selective...
Immune checkpoint inhibitors (ICIs) revolutionized the management of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers. Based on notable results observed in metastatic setting, several clinical trials investigated ICIs as neoadjuvant treatment (NAT) for localized dMMR/MSI-H GI cancers, achieving striking terms and pathological responses creating opportunity to spare patients from chemotherapy and/or radiotherapy even surgical resection....
AXL is a tyrosine kinase receptor activated by GAS6 and regulates cancer cell proliferation migration angiogenesis. We studied as new therapeutic target in colorectal (CRC). Expression activation of were evaluated panel human CRC lines. gene silencing or pharmacologic inhibition with foretinib suppressed proliferation, survival cells. In an orthotopic colon model HCT116 cells overexpressing AXL, treatment caused significant tumour growth peritoneal metastatic spreading. overexpression...
Immunotherapy has limited efficacy in metastatic colorectal cancer (mCRC). Understanding mechanisms mediating immune resistance microsatellite stable (MSS) tumors remains an ongoing challenge. Novel combination immunotherapy-based approaches have been developed under the rationale of overcoming and developing effective response against tumor cells. Preclinical studies demonstrated that cetuximab may modulate to In this scenario, inhibition PD-L1 with IgG1 MAb avelumab anti-EGFR monoclonal...